Observera att detta är en testmiljö för utveckling som inte ska
användas som underlag för klinisk bedömning. Besök Janusmed här:
https://janusmed.se
10/4/2025
Janusmed sex and gender
Janusmed sex and gender – Saknas
Janusmed Sex and Gender is a knowledge database providing information on
sex and gender aspects of drug treatment. The knowledge database is
primarily intended to be used by physicians and healthcare professionals.
The texts are general and should not be considered as treatment
guidelines. The individual patient’s physician is responsible for the
patient’s drug treatment.
Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016;26(9):1390-1400.
Schmedt N, Kollhorst B, Enders D, Jobski K, Krappweis J, Garbe E et al. Comparative risk of death in older adults treated with antipsychotics: A population-based cohort study. Eur Neuropsychopharmacol. 2016;26(9):1390-1400.
Vaccine for human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)
testing environment
Vaccine for human papillomavirus (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)
Class : A
Show all info
Print
Contact us
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
AA
AA
Vaccine for human papillomavirus (types 6, 11, 16, 18)
testing environment
Vaccine for human papillomavirus (types 6, 11, 16, 18)
Class : A
Show all info
Print
Contact us
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Gardasil/Silgard. Summary of Product Characteristics. European Medicines Agency (EMA). 2017.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-85.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Gardasil/Silgard. Summary of Product Characteristics. European Medicines Agency (EMA). 2017.
Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356:1928-43.
Olsson SE, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM et al. Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection. Hum Vaccin. 2009;5:696-704.
Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C et al. Efficacy of quadrivalent HPV vaccine against HPV Infection and disease in males. N Engl J Med. 2011;364:401-11.
FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356:1915-27.
Palefsky JM, Giuliano AR, Goldstone S, Moreira ED, Aranda C, Jessen H et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med. 2011;365:1576-85.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
AA
AA
Vaccine for human papillomavirus (types 16 and 18)
testing environment
Vaccine for human papillomavirus (types 16 and 18)
Class : A
Show all info
Print
Contact us
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Cervarix (human papillomavirus vaccine, types 16, 18). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age. Clinicaltrialsgov [www]. [cited 2017-01-09].
Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.
Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.
Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.
Paavonen J. O102 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy. Sexually Transmitted Infections. 2013;89(Suppl 1):A44-A.
Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin's vaccines (7th edition). Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds). Elsevier: Philadelphia (PA); 2018. p. 430-455.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
Gardasil/Silgard/Cervarix. EPAR - Scientific discussion. European Medicines Agency (EMA). 2006/2007.
Giuliano AR, Isaacs-Soriano K, Torres BN, Abrahamsen M, Ingles DJ, Sirak BA et al. Immunogenicity and safety of Gardasil among mid-adult aged men (27-45 years)--The MAM Study. Vaccine. 2015;33:5640-5646.
Cervarix (human papillomavirus vaccine, types 16, 18). Summary of Product Characteristics. European Medicines Agency (EMA); 2017.
Immunogenicity of GlaxoSmithKline Biological's Human Papillomavirus (HPV) Vaccine (580299) Versus Merck's Gardasil® in Healthy Females 18-45 Years of Age. Clinicaltrialsgov [www]. [cited 2017-01-09].
Pedersen C, Petaja T, Strauss G, Rumke HC, Poder A, Richardus JH et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health. 2007;40:564-71.
Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin. 2011;7:1374-86.
Petäjä T, Keränen H, Karppa T, Kawa A, Lantela S, Siitari-Mattila M et al. Immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in healthy boys aged 10-18 years. J Adolesc Health. 2009;44:33-40.
Paavonen J. O102 A Community-Randomised Phase IV Human Papillomavirus (HPV) Vaccination Trial of Vaccination Strategy. Sexually Transmitted Infections. 2013;89(Suppl 1):A44-A.
Schiller JT, Markowitz LE, Hildesheim A, Lowy DR. Human papillomavirus vaccines. In: Plotkin's vaccines (7th edition). Plotkin SA, Orenstein WA, Offit PA, Edwards KM (eds). Elsevier: Philadelphia (PA); 2018. p. 430-455.
Public Health Agency of Sweden. Human papilloma virus vaccination of boys in the Swedish national vaccination programme. 2017
AA
AA
Podophyllotoxin
testing environment
Podophyllotoxin
Class : A
Show all info
Print
Contact us
Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.
Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 05% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4:194-9.
Schwartz JB. The influence of sex on pharmacokinetics. Clin Pharmacokinet. 2003;42:107-21.
Kinghorn GR, McMillan A, Mulcahy F, Drake S, Lacey C, Bingham JS. An open, comparative, study of the efficacy of 05% podophyllotoxin lotion and 25% podophyllotoxin solution in the treatment of condylomata acuminata in males and females. Int J STD AIDS. 1993;4:194-9.